Excited to share that #DRL is at the forefront of advancing biomedical research through two innovative initiatives:
1. Expansion of primary-derived cell lines with custom immortalization services.
We're enhancing our portfolio by offering client-requested immortalization of primary cell lines using human Telomerase Reverse Transcriptase (hTERT) transfection technology. This method extends the replicative lifespan of cells by maintaining telomere length, enabling prolonged and consistent research applications. Unlike traditional methods that may alter cell characteristics, hTERT immortalization preserves the cells' original functions, providing more reliable and physiologically relevant data.
2. Development of a personalized diagnostics platform utilizing patient-derived tumor models.
We're creating a platform that integrates clinical data with genetic, transcriptomic, and drug response information obtained from patient-derived #tumormodels. This approach allows for the testing of multiple treatments on tumor replicas, closely mirroring the patient's unique cancer profile. By analyzing these models, we aim to predict individual responses to therapies, leading to more effective and tailored treatment strategies. This personalized methodology has the potential to transform cancer care by identifying the most promising treatments for each patient.
Through these initiatives, #DRL is committed to providing cutting-edge tools and services that empower researchers and clinicians to make groundbreaking discoveries and deliver #personalizedhealthcare solutions.
